14K multiple recurrence target patient population Time 2021 2022 2023 Based on first and only FDA-approved therapy for recurrent pericarditis, in-line with specialty biologics with Breakthrough Therapy and Orphan Drug designation • Payer engagement has increased awareness of recurrent pericarditis and the differentiated value of ARCALYST • The distribution network for ARCALYST was developed to provide a high and consistent level of patient support with broad access. Network pharmacies provide customized ser ...

| --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------| | | | | | | | | | First Quarter 2023 | | | | | | | | | | | | Financial Results and | | | | | | Recent Portfolio Execution | | | | --- | |--------------------------------------------------------------------------------| | | | Introduction \| Sanj K. Patel, Chief Executive Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | First Quarter 2023 Financial Results \| Mark Ragosa, Chief ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Geoff Meacham - Bank of America Operator Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Ear ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 98-1327726 (I.R ...

F EB RUARY 28, 2023 | --- | |-----------------------------------------------------------------------------------------------| | | | Introduction \| Sanj K. Patel, Chief Executive Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | Fourth Quarter and Full-Year 2022 Financial Results \| Mark Ragosa, Chief Financial Officer | | Closing Remarks \| Sanj K. Patel, Chief Executive Officer | | Q&A Session | Forward Looking Statements This presentation (together with any other stat ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer Eben Tessari - Chief Operating Officer John Paolini - Chief Medical Officer Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Geoff Meacham - Bank of America Liisa Bayko - Ev ...

Pharmacokinetic Simulations PHARMACOKINETICS (PK) LEAD-IN PROOF-OF-CONCEPT AMENDED COHORT 3 (Proof of Concept) 0 200 400 600 800 Addressable US Prevalence (in thousands) 14 KPL-404: Potentially Best-in-Class, Subcutaneously Delivered Monoclonal Antibody Inhibitor 10 11 COHORTS 1-2 (PK Lead-In) Pacific Region (Excluding Japan) Kiniksa is also eligible to receive royalties on annual net sales ranging from low-double digits to mid-teens, before fulfilling upstream financial obligations 16 • Quickly took asset ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K. Patel – Chief Executive Officer John Paolini – Chief Medical Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer Eben Tessari – Chief Operating Officer Conference Call Participants Anupam Rama – JPMorgan Paul Choi – Goldman Sachs Alex Hammond – Bank of America Operator Good day and thank you for standing ...

| --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------| | | | | | | | Third Quarter 2022 | | | | | | | | | | | | Financial Results and | | | | | NOVEMB ER 1, 2022 Agenda | --- | |--------------------------------------------------------------------------------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | Clinical Update \| John F. Paolini, Chief Medical Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | Third Quarter 2022 ...